웹 접근성 설정

Search

언어 선택

하위 메뉴 바로 가기

내용 바로 가기

여호와의 증인

한국어

Sickle Cell Disease (Pediatrics)

Prevention of Sickle Cell Crises—Pharmacological Activation of Fetal Hemoglobin in Children and Infants

Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial.

Ware RE, Davis BR, Schultz WH, Brown RC, Aygun B, Sarnaik S, Odame I, Fuh B, George A, Owen W, Luchtman-Jones L, Rogers ZR, Hilliard L, Gauger C, Piccone C, Lee MT, Kwiatkowski JL, Jackson S, Miller ST, Roberts C, Heeney MM, Kalfa TA, Nelson S, Imran H, Nottage K, Alvarez O, Rhodes M, Thompson AA, Rothman JA, Helton KJ, Roberts D, Coleman J, Bonner MJ, Kutlar A, Patel N, Wood J, Piller L, Wei P, Luden J, Mortier NA, Stuber SE, Luban NL, Cohen AR, Pressel S, Adams RJ

Source‎: Lancet 2016;387(10019):661-70.

Indexed‎: PubMed 26670617

DOI‎: 10.1016/S0140-6736(15)01041-7

http://www.ncbi.nlm.nih.gov/pubmed/26670617

Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia.

Wang WC, Oyeku SO, Luo Z, Boulet SL, Miller ST, Casella JF, Fish B, Thompson BW, Grosse SD; BABY HUG Investigators.

Source‎: Pediatrics 2013;132(4):677-83.

Indexed‎: PubMed 23999955

DOI‎: 10.1542/peds.2013-0333

http://www.ncbi.nlm.nih.gov/pubmed/23999955

Evidence review of hydroxyurea for the prevention of sickle cell complications in low-income countries.

Mulaku M, Opiyo N, Karumbi J, Kitonyi G, Thoithi G, English M.

Source‎: Arch Dis Child 2013;98(11):908-14.

Indexed‎: PubMed 23995076

DOI‎: 10.1136/archdischild-2012-302387

http://www.ncbi.nlm.nih.gov/pubmed/23995076

The effect of hydroxcarbamide therapy on survival of children with sickle cell disease.

Lobo CL, Pinto JF, Nascimento EM, Moura PG, Cardoso GP, Hankins JS.

Source‎: Br J Haematol 2013;161(6):852-60.

Indexed‎: PubMed 23590693

DOI‎: 10.1111/bjh.12323

http://www.ncbi.nlm.nih.gov/pubmed/23590693

Impact of hydroxyurea on clinical events in the BABY HUG trial.

Thornburg CD, Files BA, Luo Z, Miller ST, Kalpatthi R, Iyer R, Seaman P, Lebensburger J, Alvarez O, Thompson B, Ware RE, Wang WC; BABY HUG Investigators.

Source‎: Blood 2012;120(22):4304-10.

Indexed‎: PubMed 22915643

DOI‎: 10.1182/blood-2012-03-419879

http://www.ncbi.nlm.nih.gov/pubmed/22915643

Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).

Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP, Rana S, Thornburg CD, Rogers ZR, Kalpatthi RV, Barredo JC, Brown RC, Sarnaik SA, Howard TH, Wynn LW, Kutlar A, Armstrong FD, Files BA, Goldsmith JC, Waclawiw MA, Huang X, Thompson BW; for the BABY HUG investigators.

Source‎: Lancet 2011;377(9778):1663-72.

Indexed‎: PubMed 21571150

DOI‎: 10.1016/S0140-6736(11)60355-3

http://www.ncbi.nlm.nih.gov/pubmed/21571150

How I use hydroxyurea to treat young patients with sickle cell anemia.

Ware RE.

Source‎: Blood 2010;115(26):5300-11.

Indexed‎: PubMed 20223921

DOI‎: 10.1182/blood-2009-04-146852

http://www.ncbi.nlm.nih.gov/pubmed/20223921

Pharmacotherapy in sickle cell disease—state of the art and future prospects.

Hankins J, Aygun B.

Source‎: Br J Haematol 2009;145(3):296-308.

Indexed‎: PubMed 19222472

DOI‎: 10.1111/j.1365-2141.2009.07602.x

http://www.ncbi.nlm.nih.gov/pubmed/19222472

Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children.

Strouse JJ, Lanzkron S, Beach MC, Haywood C, Park H, Witkop C, Wilson RF, Bass EB, Segal JB.

Source‎: Pediatrics 2008;122(6):1332-42.

Indexed‎: PubMed 19047254

DOI‎: 10.1542/peds.2008-0441

http://www.ncbi.nlm.nih.gov/pubmed/19047254

Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study.

Hankins JS, Ware RE, Rogers ZR, Wynn LW, Lane PA, Scott JP, Wang WC.

Source‎: Blood 2005;106(7):2269-75.

Indexed‎: PubMed 16172253

http://www.ncbi.nlm.nih.gov/pubmed/16172253

Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease.

Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, Ware RE.

Source‎: Blood 2004;103(6):2039-45.

Indexed‎: PubMed 14630791

http://www.ncbi.nlm.nih.gov/pubmed/14630791

Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study.

Wang WC, Helms RW, Lynn HS, Redding-Lallinger R, Gee BE, Ohene-Frempong K, Smith-Whitley K, Waclawiw MA, Vichinsky EP, Styles LA, Ware RE, Kinney TR.

Source‎: J Pediatr 2002;140(2):225-9.

Indexed‎: PubMed 11865275

http://www.ncbi.nlm.nih.gov/pubmed/11865275


jw.org의 의학 부문은 주로 임상의나 다른 의료 전문가들에게 정보를 제공하기 위해 마련되었습니다. 여기서 제공하는 정보는 의료 상담이나 치료 권고 사항을 담고 있지 않으며, 의료 전문가를 대신하기 위한 목적으로 마련된 것도 아닙니다. 여기 인용된 임상 문헌은 고려할 만한 수혈 대체 치료 방안들을 간략히 보여 주기 위한 것이며, 여호와의 증인이 발행한 것은 아닙니다. 의료 전문가 각자에게는 최신 정보에 계속 관심을 갖고, 사용 가능한 치료 방법을 논의하며, 환자가 본인의 질병, 희망 사항, 가치관, 신념에 맞는 치료 방법을 선택할 수 있도록 도울 책임이 있습니다. 여기에 나오는 모든 치료 방안이 어느 환자에게든 적합하거나 받아들여지는 것은 아닙니다.

환자가 유의할 점: 질병이나 치료와 관련된 문제는 항상 의사나 다른 의료 전문가의 조언을 구하십시오. 아픈 것 같다면 의사와 상담하십시오.

본 웹사이트의 이용은 이 사이트 약관의 제약을 받습니다.